Braveheart Bio, Inc. Common Stock (BRVE) — Working Capital to Net Assets Ratio

Latest as of March 2026: -90.7%

Braveheart Bio, Inc. Common Stock (BRVE) has a Working Capital to Net Assets ratio of -90.7% as of March 2026. Working capital of $71.07 Million (current assets of $81.07 Million minus current liabilities of $10.00 Million) is measured against net assets of $-78.39 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. For the complete balance sheet picture, see how large is Braveheart Bio, Inc. Common Stock's balance sheet.

WC/NA Ratio

-90.7%
Working Capital / Net Assets

Working Capital

$71.07 Million
USD

Current Assets

$81.07 Million
USD

Current Liabilities

$10.00 Million
USD

Annual Working Capital to Net Assets for Braveheart Bio, Inc. Common Stock (None–None)

The table below presents the year-by-year Working Capital to Net Assets ratio for Braveheart Bio, Inc. Common Stock from None to None, covering 0 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. Read Braveheart Bio, Inc. Common Stock balance sheet liabilities for a breakdown of total debt and financial obligations.

Year WC/NA Ratio Working Capital (USD) Net Assets Current Assets Current Liabilities Change (pp)
pp = percentage points